Compare Star Bulk Carriers Corp (SBLK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Star Bulk Carriers Corp pays a 6.79% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| SBLK | XBI | |
|---|---|---|
Market Cap | $3.09B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $29.15 | $164.28 |
52-Week Low | $16.79 | $86.92 |
Enterprise Value | $3.77B | — |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $27.89, down 1.86% on the day, amid a bullish technical signal and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Valuation metrics appear attractive with a P/E of 10.85 and EV/EBITDA of 7.46, while profitability improved significantly with a net margin of 23.87% in 2026. Recent news highlights dividend declarations and strong operational results.
Outlook remains positive driven by earnings beats and healthy cash flow, though risks include dry bulk rate volatility and competitive pressures. Analyst consensus is bullish with 14 buy ratings, supporting potential upside, but investors should monitor shipping market cycles and debt levels.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
